FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224304433> ?p ?o ?g. }

• W4224304433 abstract "Genomic aberrations in the cell cycle and PI3K/Akt/mTOR pathways have been reported in diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG). Dual inhibition of CDK4/6 and mTOR has biologic rationale and minimal overlapping toxicities. This study determined the recommended phase 2 dose (RP2D) of ribociclib and everolimus following radiotherapy in children with DIPG and HGG.Patients were enrolled according to a Rolling-6 design and received ribociclib and everolimus once daily for 21 and 28 days, respectively. All patients with HGG and biopsied DIPG were screened for retinoblastoma protein presence by immunohistochemistry. Pharmacokinetics were analyzed.Nineteen patients enrolled (median age: 8 years [range: 2-18]). Three patients enrolled at each dose level 1 and 2 without dose-limiting toxicities (DLT). Thirteen patients were enrolled at dose level 3, with one patient experiencing a DLT (grade 3 infection). One patient came off therapy before cycle 9 due to cardiac toxicity. The most common grade 3/4 toxicities were neutropenia (33%), leucopenia (17%), and lymphopenia (11%). Steady-state everolimus exposures in combination were 1.9 ± 0.9-fold higher than single-agent administration. Median overall survival for 15 patients with DIPG was 13.9 months; median event-free survival for four patients with HGG was 10.5 months. Two longer survivors had tumor molecular profiling identifying CDKN2A/B deletion and CDK4 overexpression.The combination of ribociclib and everolimus following radiotherapy in children with newly diagnosed DIPG and HGG was well tolerated, with a RP2D of ribociclib 170 mg/m2 and everolimus 1.5 mg/m2. Results will inform a molecularly guided phase II study underway to evaluate efficacy." @default.
• W4224304433 created "2022-04-26" @default.
• W4224304433 creator A5001013178 @default.
• W4224304433 creator A5002306055 @default.
• W4224304433 creator A5012920072 @default.
• W4224304433 creator A5013674778 @default.
• W4224304433 creator A5015655074 @default.
• W4224304433 creator A5016983624 @default.
• W4224304433 creator A5027676114 @default.
• W4224304433 creator A5037593758 @default.
• W4224304433 creator A5041913264 @default.
• W4224304433 creator A5043293908 @default.
• W4224304433 creator A5044016543 @default.
• W4224304433 creator A5045064484 @default.
• W4224304433 creator A5049469167 @default.
• W4224304433 creator A5050569696 @default.
• W4224304433 creator A5051021794 @default.
• W4224304433 creator A5060988862 @default.
• W4224304433 creator A5061208871 @default.
• W4224304433 creator A5066612645 @default.
• W4224304433 creator A5066680514 @default.
• W4224304433 creator A5067969166 @default.
• W4224304433 creator A5071378074 @default.
• W4224304433 creator A5072200377 @default.
• W4224304433 creator A5079985975 @default.
• W4224304433 creator A5083715066 @default.
• W4224304433 date "2022-01-01" @default.
• W4224304433 modified "2023-10-13" @default.
• W4224304433 title "Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report" @default.
• W4224304433 cites W1488683804 @default.
• W4224304433 cites W1981711832 @default.
• W4224304433 cites W1984026103 @default.
• W4224304433 cites W1991054314 @default.
• W4224304433 cites W2003422441 @default.
• W4224304433 cites W2008171713 @default.
• W4224304433 cites W2010493387 @default.
• W4224304433 cites W2027576483 @default.
• W4224304433 cites W2053349906 @default.
• W4224304433 cites W2069434008 @default.
• W4224304433 cites W2086053684 @default.
• W4224304433 cites W2094073838 @default.
• W4224304433 cites W2104438003 @default.
• W4224304433 cites W2118677643 @default.
• W4224304433 cites W2124065041 @default.
• W4224304433 cites W2127758887 @default.
• W4224304433 cites W2139802897 @default.
• W4224304433 cites W2140193951 @default.
• W4224304433 cites W2145755261 @default.
• W4224304433 cites W2148977460 @default.
• W4224304433 cites W2155018172 @default.
• W4224304433 cites W2162643152 @default.
• W4224304433 cites W2167746858 @default.
• W4224304433 cites W2219817965 @default.
• W4224304433 cites W2513801928 @default.
• W4224304433 cites W2529242108 @default.
• W4224304433 cites W2598017183 @default.
• W4224304433 cites W2605858714 @default.
• W4224304433 cites W2611651965 @default.
• W4224304433 cites W2616008385 @default.
• W4224304433 cites W2745695523 @default.
• W4224304433 cites W2751187578 @default.
• W4224304433 cites W2791924207 @default.
• W4224304433 cites W2802016878 @default.
• W4224304433 cites W3002499004 @default.
• W4224304433 cites W3037437652 @default.
• W4224304433 cites W3092538239 @default.
• W4224304433 cites W3128433493 @default.
• W4224304433 cites W3137610496 @default.
• W4224304433 cites W4205304754 @default.
• W4224304433 cites W4211132876 @default.
• W4224304433 doi "https://doi.org/10.1093/noajnl/vdac055" @default.
• W4224304433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35611273" @default.
• W4224304433 hasPublicationYear "2022" @default.
• W4224304433 type Work @default.
• W4224304433 citedByCount "3" @default.
• W4224304433 countsByYear W42243044332023 @default.
• W4224304433 crossrefType "journal-article" @default.
• W4224304433 hasAuthorship W4224304433A5001013178 @default.
• W4224304433 hasAuthorship W4224304433A5002306055 @default.
• W4224304433 hasAuthorship W4224304433A5012920072 @default.
• W4224304433 hasAuthorship W4224304433A5013674778 @default.
• W4224304433 hasAuthorship W4224304433A5015655074 @default.
• W4224304433 hasAuthorship W4224304433A5016983624 @default.
• W4224304433 hasAuthorship W4224304433A5027676114 @default.
• W4224304433 hasAuthorship W4224304433A5037593758 @default.
• W4224304433 hasAuthorship W4224304433A5041913264 @default.
• W4224304433 hasAuthorship W4224304433A5043293908 @default.
• W4224304433 hasAuthorship W4224304433A5044016543 @default.
• W4224304433 hasAuthorship W4224304433A5045064484 @default.
• W4224304433 hasAuthorship W4224304433A5049469167 @default.
• W4224304433 hasAuthorship W4224304433A5050569696 @default.
• W4224304433 hasAuthorship W4224304433A5051021794 @default.
• W4224304433 hasAuthorship W4224304433A5060988862 @default.
• W4224304433 hasAuthorship W4224304433A5061208871 @default.
• W4224304433 hasAuthorship W4224304433A5066612645 @default.
• W4224304433 hasAuthorship W4224304433A5066680514 @default.
• W4224304433 hasAuthorship W4224304433A5067969166 @default.
• W4224304433 hasAuthorship W4224304433A5071378074 @default.
• W4224304433 hasAuthorship W4224304433A5072200377 @default.
• W4224304433 hasAuthorship W4224304433A5079985975 @default.

• next